Fairmount Funds Management LLC bought CBIO
July 16, 2026 · Form 4 insider transaction
Fairmount Funds Management LLC bought 853,450 shares of Crescent Biopharma, Inc. at $14.50 per share, a transaction worth $12.38M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
853,450
Price
$14.50
Total value
$12.38M
RoleDirector, 10% owner
SecurityOrdinary Shares
Transaction codeP: Open-market purchase
Transaction dateJuly 16, 2026
Filing dateJuly 20, 2026
Shares owned after3,601,316
OwnershipIndirect
10b5-1 planNo
AmendedNo
Footnotes
Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.